Objective: To explore the clinical effect of Yiqiweixue Tablets combined with Ferrous Succinate Tablets in the treatment of anemia in pregnancy, and the impact on pregnancy outcomes. Methods: A total of 70 patients with anemia in pregnancy who were admitted to the hospital from May 2023 to May 2025 were selected for this study. They were divided into the control group (35 cases treated with Ferrous Succinate Tablets alone) and the treatment group (35 cases treated with Yiqiweixue Tablets combined with Ferrous Succinate Tablets) using a random number table. Both groups were treated for 4 weeks. Hemoglobin (Hb), red blood cell count (RBC), hematocrit (HCT), mean corpuscular volume (MCV), serum iron (SI), serum ferritin (SF), transferrin saturation (TSAT) before and after treatment were compared between the two groups. Adverse reactions and pregnancy outcomes were statistically analyzed. Results: After treatment, both groups showed significant increases in the levels of Hb, RBC, HCT, MCV, SI, SF, and TSAT (P<0.05). Meanwhile, all of above indicators in the treatment group were significantly higher than those in the control group (P<0.05). No statistically significant difference was found in adverse reactions, neonatal birth weight, incidence of premature delivery, and cesarean section rate between the two groups (P>0.05). Conclusion: Compared to the treatment with Ferrous Succinate Tablets alone, the combined treatment with Yiqiweixue Tablets and Ferrous Succinate Tablets can better improve anemia and iron metabolism indicators in patients with anemia in pregnancy, without increase in the risk of adverse pregnancy outcomes.